Acoustic Processing of Fluidic Samples for Planetary Exploration

The search for life on other planetary bodies is driven by our quest to determine if Earth is unique with respect to harboring life. In order to answer this question, instrumentation with suitable sensitivity is required to measure biosignatures. In addition to accurate measurements by in-situ instruments, specialized sample acquisition and sample handling hardware is required to maximize the scientific information obtained from an acquired sample. This paper discusses a class of compact sample processing instrumentation using solid-state mechanisms that use acoustic waves to process samples prior to delivery to the instrument. Some of the acoustic sample processes that can be used to aid in preparation of liquid and liquid/solid mixtures include: mixing, milling, cavitating, lysing, heating, streaming, stirring, lofting, concentrating, segregating, and filtering. We will review these acoustic processes and show how they are generated using electromechanical systems. In addition to processing, these transduction systems could also use acoustics to interrogate physical properties such as the state of the sample, the acoustic velocity, and its attenuation. In order to generate these processes and sensing capabilities at these frequencies, a transduction mechanism is required to produce stress waves from electrical signals and vice versa. One commonly used technique is to use piezoelectric transducers that generate a stress that is linearly proportional to the voltage across the transducer and a voltage that is proportional to the stress on a transducer’s face. A variety of transducer modes are available to excite the sample, including thickness, transverse, radial, and shear extensional, and these can be used to build composite resonance structures including ultrasonic horns, tuning forks, bimorph, and unimorph benders to increase stress generated in the sample. We discuss how to model the acoustic interactions with the sample and the sample chamber in order to produce the required stress waves and illustrate the use of network models of piezoelectric transducers to accomplish this modeling. We demonstrate how to build up these models using Mason’s equivalent circuit for a piezoelectric and network models for acoustic layers in a design. Finally, to illustrate this acoustic processing ability, we will discuss a few systems that we have developed for sample handling systems for other planetary bodies like Mars and ocean worlds Enceladus and Europa

Self-management for osteoarthritis of the knee: Does mode of delivery influence outcome?

Background Self-management has become increasingly popular in the management of chronic diseases. There are many different self-management models. Meta analyses of arthritis self-management have concluded that it is difficult to recommend any one program in preference to another due to inconsistencies in the study designs used to evaluate different programs. The Stanford Arthritis Self-Management Program (ASMP), most commonly delivered by trained lay leaders, is a generic program widely used for people with rheumatological disorders. We have developed a more specific program expressly for people with osteoarthritis of the knee (OAKP). It includes information designed to be delivered by health professionals and results in improvements in pain, function and quality of life. Aim: To determine whether, for people with osteoarthritis (OA) of the knee, the OAKP implemented in a primary health care setting can achieve and maintain clinically meaningful improvements in more participants than ASMP delivered in the same environment. Methods/Design The effectiveness of the programs will be compared in a single-blind randomized study. Participants: 146 participants with established OA knee will be recruited. Volunteers with coexistent inflammatory joint disease or serious co-morbidities will be excluded. Interventions: Participants will be randomised into either OAKP or ASMP groups and followed for 6 months. Measurements: Assessments will be immediately before and after the intervention and at 6 months. Primary outcome measures will be WOMAC and SF-36 questionnaires and a VAS for pain. Secondary outcomes will include balance, tested using a timed single leg balance test and a timed step test and self-efficacy. Data will be analysed using repeated measures ANOVA. Discussion With an aging population the health care costs for people with arthritis are ever increasing. Although cost analysis is beyond the scope of this study, it is reasonable to expect that costs will be greater when health professionals deliver self-management programs as opposed to lay leaders. Consequently it is critical to examine the relative effectiveness of the primary care management strategies available for OA

Effects of Anacetrapib in Patients with Atherosclerotic Vascular Disease

BACKGROUND: Patients with atherosclerotic vascular disease remain at high risk for cardiovascular events despite effective statin-based treatment of low-density lipoprotein (LDL) cholesterol levels. The inhibition of cholesteryl ester transfer protein (CETP) by anacetrapib reduces LDL cholesterol levels and increases high-density lipoprotein (HDL) cholesterol levels. However, trials of other CETP inhibitors have shown neutral or adverse effects on cardiovascular outcomes. METHODS: We conducted a randomized, double-blind, placebo-controlled trial involving 30,449 adults with atherosclerotic vascular disease who were receiving intensive atorvastatin therapy and who had a mean LDL cholesterol level of 61 mg per deciliter (1.58 mmol per liter), a mean non-HDL cholesterol level of 92 mg per deciliter (2.38 mmol per liter), and a mean HDL cholesterol level of 40 mg per deciliter (1.03 mmol per liter). The patients were assigned to receive either 100 mg of anacetrapib once daily (15,225 patients) or matching placebo (15,224 patients). The primary outcome was the first major coronary event, a composite of coronary death, myocardial infarction, or coronary revascularization. RESULTS: During the median follow-up period of 4.1 years, the primary outcome occurred in significantly fewer patients in the anacetrapib group than in the placebo group (1640 of 15,225 patients [10.8%] vs. 1803 of 15,224 patients [11.8%]; rate ratio, 0.91; 95% confidence interval, 0.85 to 0.97; P=0.004). The relative difference in risk was similar across multiple prespecified subgroups. At the trial midpoint, the mean level of HDL cholesterol was higher by 43 mg per deciliter (1.12 mmol per liter) in the anacetrapib group than in the placebo group (a relative difference of 104%), and the mean level of non-HDL cholesterol was lower by 17 mg per deciliter (0.44 mmol per liter), a relative difference of -18%. There were no significant between-group differences in the risk of death, cancer, or other serious adverse events. CONCLUSIONS: Among patients with atherosclerotic vascular disease who were receiving intensive statin therapy, the use of anacetrapib resulted in a lower incidence of major coronary events than the use of placebo. (Funded by Merck and others; Current Controlled Trials number, ISRCTN48678192 ; ClinicalTrials.gov number, NCT01252953 ; and EudraCT number, 2010-023467-18 .)

Providing Enhanced Migration Time Reproducibility with a High-Voltage-Compatible Flow Sensor for Capillary Electrophoresis

In capillary electrophoresis (CE), analyte identification is primarily based on migration time, which is a function of the analyte’s electrophoretic mobility and the electro-osmotic flow (EOF). The migration time can be impacted by the presence of parasitic flow from changes in temperature or pressure during the run. Presented here is a high-voltage-compatible flow sensor capable of monitoring the volumetric flow inside the capillary during a separation with nL/min resolution. The direct measurement of both flow and time allows for compensation of flow instabilities. By expressing the electropherogram in terms of signal versus electromigration velocity instead of time, it is possible to improve the run-to-run reproducibility up to 25×

Europan Molecular Indicators of Life Investigation (EMILI) Technology Development

International audienceThe Europan Molecular Indicators of Life Investigation (EMILI), funded under the ICEE-2 program, is designed to meet the scientific requirements of the Europa Lander's Organic Composition Analyzer, as well as the stringent resource and environmental tolerance constraints mandated by the Lander implementation. EMILI tightly couples two complementary analytical techniques, based on (i) liquid processing with capillary electrophoresis and (ii) pyrolysis/derivatization with gas chromatography, to robustly detect, structurally characterize, and quantify the broadest range of organics and other chemicals that may be present over widely-varying concentrations

Europan Molecular Indicators of Life Investigation (EMILI) (Invited)

International audienceThe Europan Molecular Indicators of Life Investigation (EMILI) is an instrument concept under development for a potential future landed mission to Europa. The goal of EMILI is to help search for potential molecular biosignatures in samples collected from the icy surface. The sample material may contain compounds that originated in the subsurface ocean on Europa, and have migrated to the surface. Key classes of organic molecules as well as patterns of molecular groups could be indicative of life. To detect the widest possible range of such compounds, EMILI includes both capillary electrophoresis and gas chromatography sample processing and separation systems, as well as detectors based on laser fluorescence, conductivity, and mass spectrometry, in an integrated instrument package

Europan Molecular Indicators of Life Investigation (EMILI) for a Future Europa Lander Mission

International audienceThe Europan Molecular Indicators of Life Investigation (EMILI) is an instrument concept being developed for the Europa Lander mission currently under study. EMILI will meet and exceed the scientific and technical/resource requirements of the organic composition analyzer identified as a core instrument on the Lander. EMILI tightly couples two complementary analytical techniques, based on 1) liquid extraction and processing with capillary electrophoresis and 2) thermal and chemical extraction with gas chromatography, to robustly detect, structurally characterize, and quantify the broadest range of organics and other Europan chemicals over widely-varying concentrations. Dual processing and analysis paths enable EMILI to perform a thorough characterization of potential molecular biosignatures and contextual compounds in collected surface samples. Here we present a summary of the requirements, design, and development status of EMILI with projected scientific opportunities on the Europa Lander as well as on other potential life detection missions seeking potential molecular biosignatures in situ

Europan Molecular Indicators of Life Investigation (EMILI) for a Future Europa Lander Mission

International audienceThe Europan Molecular Indicators of Life Investigation (EMILI) is an instrument concept being developed for the Europa Lander mission currently under study. EMILI will meet and exceed the scientific and technical/resource requirements of the organic composition analyzer identified as a core instrument on the Lander. EMILI tightly couples two complementary analytical techniques, based on 1) liquid extraction and processing with capillary electrophoresis and 2) thermal and chemical extraction with gas chromatography, to robustly detect, structurally characterize, and quantify the broadest range of organics and other Europan chemicals over widely-varying concentrations. Dual processing and analysis paths enable EMILI to perform a thorough characterization of potential molecular biosignatures and contextual compounds in collected surface samples. Here we present a summary of the requirements, design, and development status of EMILI with projected scientific opportunities on the Europa Lander as well as on other potential life detection missions seeking potential molecular biosignatures in situ